Evidence map›Paper›PMID 34717586›Full record

SynthesisBMC infectious diseases2021

Hepatitis B virus infection in Nigeria: a systematic review and meta-analysis of data published between 2010 and 2019.

Busayo I Ajuwon, Isabelle Yujuico, Katrina Roper, Alice Richardson, Meru Sheel, Brett A Lidbury

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 11 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 11 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Busayo I AjuwonResearch School of Population Health, ANU College of Health and Medicine, The Australian National University, Acton, ACT, Australia. busayo.ajuwon@anu.edu.au.
Isabelle YujuicoResearch School of Population Health, ANU College of Health and Medicine, The Australian National University, Acton, ACT, Australia.
Katrina RoperResearch School of Population Health, ANU College of Health and Medicine, The Australian National University, Acton, ACT, Australia.
Alice RichardsonStatistical Consulting Unit, The Australian National University, Acton, ACT, Australia.
Meru SheelResearch School of Population Health, ANU College of Health and Medicine, The Australian National University, Acton, ACT, Australia.
Brett A LidburyResearch School of Population Health, ANU College of Health and Medicine, The Australian National University, Acton, ACT, Australia.
Australian National University · AU

Funding

Australian Commonwealth Department of Health Quality Use of Pathology Programme (QUPP) Funding 4-2UJWED1Australian National Health and Medical Research Ideas Grant 1184720
6 · The paper itself

Abstract

backgroundHepatitis B virus (HBV) is an infectious disease of global significance, causing a significant health burden in Africa due to complications associated with infection, such as cirrhosis and liver cancer. In Nigeria, which is considered a high prevalence country, estimates of HBV cases are inconsistent, and therefore additional clarity is required to manage HBV-associated public health challenges.

methodsA systematic review of the literature (via PubMed, Advanced Google Scholar, African Index Medicus) was conducted to retrieve primary studies published between 1 January 2010 and 31 December 2019, with a random-effects model based on proportions used to estimate the population-based prevalence of HBV in the Nigerian population.

resultsThe final analyses included 47 studies with 21,702 participants that revealed a pooled prevalence of 9.5%. A prevalence estimate above 8% in a population is classified as high. Sub-group analyses revealed the highest HBV prevalence in rural settings (10.7%). The North West region had the highest prevalence (12.1%) among Nigeria's six geopolitical zones/regions. The estimate of total variation between studies indicated substantial heterogeneity. These variations could be explained by setting and geographical region. The statistical test for Egger's regression showed no evidence of publication bias (p = 0.879).

conclusionsWe present an up-to-date review on the prevalence of HBV in Nigeria, which will provide critical data to optimise and assess the impact of current prevention and control strategies, including disease surveillance and diagnoses, vaccination policies and management for those infected.

Indexed as

Hepatitis BHepatitis B virusHepatitis B Surface AntigensHumansNigeriaPrevalenceHepatitis B Surface Antigens

Identifiers

PMID34717586
PMCPMC8556927
OpenAlexW3209575834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.